Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...

Crinetics Pharmaceuticals announced that it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, highlighting the investigational treatment ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

Enrollment in the Advance OLE study was offered to participants from the Phase 2 ACROBAT Evolve and Edge studies of acromegaly patients who were under a variety of degrees of baseline biochemical ...

A Prescription Drug User Fee Act target date of September 25, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine ...

October 13, 2010 (Liege, Belgium) — In patients with treatment-resistant, active acromegaly, normalizing insulin-like growth factor 1 (IGF-1) levels leads to a marked reduction in cardiovascular risk, ...

Please provide your email address to receive an email when new articles are posted on . An AI model correctly identified 22 of 31 adults as having acromegaly strictly based on voice recordings. The ...

Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...